Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX) have received an average rating of “Hold” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $11.8750.

Several research firms recently issued reports on NVAX. HC Wainwright increased their target price on Novavax from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. BTIG Research reissued a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Tuesday, January 20th. Jefferies Financial Group reissued a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. B. Riley Financial reissued a “buy” rating on shares of Novavax in a research note on Thursday. Finally, Weiss Ratings raised Novavax from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th.

Novavax Stock Performance

Novavax stock opened at $8.12 on Monday. Novavax has a fifty-two week low of $5.35 and a fifty-two week high of $11.97. The firm has a 50 day moving average price of $9.15 and a 200 day moving average price of $8.25. The company has a market capitalization of $1.32 billion, a PE ratio of 3.37 and a beta of 2.65.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.77. Novavax had a net margin of 39.19% and a negative return on equity of 673.17%. The firm had revenue of $136.40 million during the quarter, compared to the consensus estimate of $90.26 million. During the same quarter last year, the firm earned ($0.51) EPS. The firm’s revenue for the quarter was up 66.6% on a year-over-year basis. As a group, equities research analysts forecast that Novavax will post -1.46 earnings per share for the current year.

Hedge Funds Weigh In On Novavax

Hedge funds have recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new position in Novavax during the 4th quarter worth about $33,000. Quarry LP acquired a new position in Novavax during the 3rd quarter worth about $33,000. State of Wyoming acquired a new position in Novavax during the 2nd quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. raised its position in Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,617 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in Novavax in the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.